© 2019 Helomics Corp. All rights reserved.

  • White Twitter Icon
  • Facebook - White Circle
  • White LinkedIn Icon

Helomics® Awarded Federal Supply Schedule (FSS) Contract

June 9, 2016

 

 

Helomics® Corporation, a privately-held, personalized healthcare company that provides comprehensive tumor profiling utilizing proprietary tissue-based live cell and fixed cell products and services, announced today that the National Acquisition Center of the Department of Veterans Affairs has awarded the company a Federal Supply Schedule (FSS) Contract V797D-506041,effective June 1, 2016 through May 31, 2021. The awarding of this contract will provide all government facilities, including those operated by the U.S. Department of Veterans Affairs (VA) and Department of Defense (DoD), easy access to Helomics’ ChemoFx® tumor profiling test.

 

ChemoFx provides tumor-specific information to assist physicians in the identification of ineffective and effective chemotherapies for an individual patient’s tumor. By determining the sensitivity of tumor cells to certain drugs, the test helps physicians identify the drugs most likely to impact the patient’s tumor, sparing patients months of undergoing ineffective treatment and the costs associated with such treatment.

 

“We are honored to receive this FSS contract, which will allow us to expand the accessibility of ChemoFx to all government institutions, including those serving our veterans and soldiers,” commented Neil Campbell, President & CEO of Helomics. “We are proud to provide the only personalized medicine test that is performed on live cell tissue from the patient’s tumor.  Utilizing live cell tissue samples allows us to provide cancer patients with accurate personalized information on the effect different chemotherapies will have on their cancer, leading to targeted and more effective treatment.”

 

 

 

 

 

This release may contain forward-looking statements that involve risks and uncertainties. Market conditions and other important factors could cause actual results to differ materially from those communicated in any forward-looking statements, information disclosed in presentations, conference calls or other public venues. We do not intend to update any forward-looking statements after the date of this press release.

Share on Facebook
Share on Twitter
Please reload

Featured Posts

Interpace Diagnostics Enters Agreement with Predictive Oncology to Enhance Diagnosis of Thyroid Cancer Via AI-Driven Analysis

September 10, 2019

1/10
Please reload

Recent Posts